These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2410765)

  • 21. [LHRH analogs--a new treatment in hormone-dependent tumors].
    Wilking N; Rutqvist LE; Theve T
    Lakartidningen; 1988 Feb; 85(8):620-3. PubMed ID: 3280927
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 23. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H
    Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664
    [No Abstract]   [Full Text] [Related]  

  • 27. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
    [No Abstract]   [Full Text] [Related]  

  • 29. Gonadotrophin releasing hormone analogues for advanced prostate cancer.
    Drug Ther Bull; 1992 Aug; 30(17):65-7. PubMed ID: 1396111
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
    Smith MR; Boyce SP; Moyneur E; Duh MS; Raut MK; Brandman J
    J Urol; 2006 Jan; 175(1):136-9; discussion 139. PubMed ID: 16406890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New prostate cancer drugs: few CV effects?
    Henahan J
    JAMA; 1983 Oct; 250(16):2097-9. PubMed ID: 6413706
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of newly diagnosed metastatic carcinoma of the prostate.
    Elder JS; Catalona WJ
    Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 39. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of advanced prostate cancer.
    Lynch JH
    J Fam Pract; 1993 Nov; 37(5):488-94. PubMed ID: 7693859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.